MCID: NDL021
MIFTS: 43

Nodular Lymphocyte Predominant Hodgkin Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards integrated aliases for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 60 74
Nlphl 60

Characteristics:

Orphanet epidemiological data:

60
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to lymphoma, hodgkin, classic and lymphoma. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and T cell receptor signaling pathway. Affiliated tissues include b cells, t cells and bone, and related phenotypes are immunodeficiency and lymphadenopathy

Wikipedia : 77 Nodular lymphocyte predominant Hodgkin''s lymphoma (NLPHL) is an indolent CD20(+) form of... more...

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 33.4 BCL6 PAX5
2 lymphoma 31.6 BCL6 PAX5 REL
3 diffuse large b-cell lymphoma 30.1 BCL6 IRF4 REL
4 primary mediastinal large b-cell lymphoma 30.1 BCL6 IRF4
5 follicular lymphoma 29.8 BCL6 IRF4
6 lymphoma, non-hodgkin, familial 29.7 BCL6 IRF4 PAX5
7 t-cell/histiocyte rich large b cell lymphoma 11.9
8 hodgkin's granuloma 10.8
9 peripheral t-cell lymphoma 10.3
10 progressive transformation of germinal centers 10.3
11 composite lymphoma 10.2 BCL6 PAX5
12 intraocular lymphoma 10.1 BCL6 PAX5
13 primary central nervous system lymphoma 10.1 BCL6 PAX5
14 multicentric castleman disease 10.1 BCL6 PAX5
15 castleman disease 10.1 BCL6 PAX5
16 kaposi sarcoma 10.1
17 li-fraumeni syndrome 10.1
18 anemia, autoimmune hemolytic 10.1
19 li-fraumeni syndrome 2 10.1
20 acute liver failure 10.1
21 anaplastic large cell lymphoma 10.1
22 hemolytic anemia 10.1
23 sarcoma 10.1
24 cauda equina syndrome 10.1
25 leiomyoma 10.1
26 polyradiculopathy 10.1
27 adult lymphoma 10.1
28 exophthalmos 10.1
29 mycobacterium avium complex infections 10.1
30 warthin tumor 10.1
31 rapidly involuting congenital hemangioma 10.1
32 lung lymphoma 10.1 BCL6 PAX5
33 splenic marginal zone lymphoma 10.1 BCL6 PAX5
34 angioimmunoblastic t-cell lymphoma 10.0 BCL6 PDCD1
35 reticulosarcoma 10.0 BCL6 PAX5
36 primary mediastinal b-cell lymphoma 10.0 BCL6 REL
37 colon lymphoma 9.9 BCL6 IRF4
38 primary effusion lymphoma 9.9 BCL6 IRF4
39 central nervous system hematologic cancer 9.9 BCL6 IRF4
40 hematologic cancer 9.8 BCL6 NFKBIA PAX5
41 marginal zone b-cell lymphoma 9.8 BCL6 IRF4
42 mediastinal malignant lymphoma 9.8 BCL6 PAX5 REL
43 leukemia, chronic lymphocytic 9.8 BCL6 NFKBIA PAX5
44 leukocyte disease 9.7 BCL6 IRF4 PAX5
45 lymphoma, mucosa-associated lymphoid type 9.7 BCL6 IRF4
46 adult t-cell leukemia 9.5 IRF4 NFKBIA
47 b-cell lymphomas 9.3 BCL6 IRF4 PAX5 REL

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

60 33 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 immunodeficiency 60 33 hallmark (90%) Very frequent (99-80%) HP:0002721
2 lymphadenopathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0002716
3 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
4 hyperhidrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000975
5 splenomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0001744
6 hepatomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0002240
7 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
8 pruritus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000989
9 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
10 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
11 breast carcinoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0003002
12 abnormality of bone marrow cell morphology 60 33 occasional (7.5%) Occasional (29-5%) HP:0005561
13 b-cell lymphoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0012191
14 lymphoma 60 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 BCL6 IRF4 NFKBIA PAX5 PDCD1 REL
2 growth/size/body region MP:0005378 9.63 BCL6 IRF4 NFKBIA PAX5 PDCD1 REL
3 hematopoietic system MP:0005397 9.43 BCL6 IRF4 NFKBIA PAX5 PDCD1 REL
4 immune system MP:0005387 9.1 BCL6 IRF4 NFKBIA PAX5 PDCD1 REL

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search Clinical Trials , NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

42
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Colon, Small Intestine

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 172)
# Title Authors Year
1
Validation of CD137 Immunohistochemical Stain on Paraffin-Embedded Tissue as a Marker to Facilitate Distinction Between Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, and Anaplastic Large Cell Lymphoma. ( 30816829 )
2019
2
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. ( 31036721 )
2019
3
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. ( 30770396 )
2019
4
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. ( 30485408 )
2019
5
To treat or not to treat, that is the NLPHL question. ( 31097532 )
2019
6
Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 30155322 )
2018
7
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. ( 28902083 )
2018
8
A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma. ( 30259184 )
2018
9
Multiple Cavitary Lung Lesions in an Adolescent: Case Report of a Rare Presentation of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 30102646 )
2018
10
Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? ( 28369705 )
2018
11
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28737231 )
2018
12
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2018
13
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. ( 28802087 )
2018
14
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. ( 28971503 )
2018
15
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29309302 )
2018
16
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127. ( 29351228 )
2018
17
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29401099 )
2018
18
Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29413265 )
2018
19
Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. ( 29479868 )
2018
20
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29537344 )
2018
21
Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29719928 )
2018
22
Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. ( 29893471 )
2018
23
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. ( 30064977 )
2018
24
A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide. ( 29552367 )
2018
25
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. ( 26913966 )
2017
26
Nodular Lymphocyte Predominant Hodgkin Lymphoma Presenting With Unilateral Orbital Involvement. ( 27015240 )
2017
27
Atypical variants of nodular lymphocyte-predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. ( 27816718 )
2017
28
A case of composite classical and nodular lymphocyte predominant Hodgkin lymphoma with progression to diffuse large B-cell non-Hodgkin lymphoma: Diagnostic difficulty in fine-needle aspiration cytology. ( 27888658 )
2017
29
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
30
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
31
T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28183747 )
2017
32
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups. ( 28220934 )
2017
33
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. ( 28233899 )
2017
34
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. ( 28522441 )
2017
35
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. ( 28851661 )
2017
36
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. ( 28877074 )
2017
37
Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015. ( 28935378 )
2017
38
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. ( 29222274 )
2017
39
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. ( 29230339 )
2017
40
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Progressive Transformation of Germinal Centers. ( 29348956 )
2017
41
R-CHOP in NLPHL: who should receive it? ( 28751354 )
2017
42
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
43
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. ( 26585412 )
2016
44
Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. ( 26658840 )
2016
45
Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. ( 26685097 )
2016
46
Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26712878 )
2016
47
A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. ( 26732883 )
2016
48
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. ( 26762971 )
2016
49
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. ( 26837698 )
2016
50
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. ( 26872637 )
2016

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Pathways related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 BCL6 NFKBIA REL
2
Show member pathways
11.99 IRF4 NFKBIA PDCD1 REL
3
Show member pathways
11.94 BCL6 NFKBIA REL
4 11.85 BCL6 PAX5 REL
5 11.66 BCL6 IRF4
6
Show member pathways
11.65 NFKBIA REL
7
Show member pathways
11.63 BCL6 IRF4 NFKBIA REL
8 11.61 BCL6 IRF4 NFKBIA PAX5 PDCD1 REL
9
Show member pathways
11.47 IRF4 NFKBIA REL
10
Show member pathways
11.45 NFKBIA REL
11 11.43 NFKBIA REL
12 11.37 BCL6 IRF4
13
Show member pathways
11.36 NFKBIA REL
14
Show member pathways
11.3 NFKBIA REL
15
Show member pathways
11.28 NFKBIA REL
16 11.27 NFKBIA REL
17
Show member pathways
11.22 NFKBIA REL
18 11.16 BCL6 PAX5 PDCD1
19 11.14 NFKBIA REL
20 11.09 NFKBIA REL
21 10.95 NFKBIA PDCD1
22
Show member pathways
10.91 NFKBIA REL
23 10.51 NFKBIA REL

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Cellular components related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.02 BCL6 IRF4 NFKBIA PAX5 REL

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.58 IRF4 NFKBIA REL
2 negative regulation of apoptotic process GO:0043066 9.5 BCL6 NFKBIA PDCD1
3 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.26 NFKBIA REL
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.26 IRF4 NFKBIA PAX5 REL
5 humoral immune response GO:0006959 9.16 PAX5 PDCD1
6 transcription by RNA polymerase II GO:0006366 9.07 PAX5
7 negative regulation of Notch signaling pathway GO:0045746 8.62 BCL6 NFKBIA

Molecular functions related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.33 BCL6 IRF4 REL
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.26 BCL6 IRF4 PAX5 REL
3 DNA-binding transcription factor activity GO:0003700 8.92 BCL6 IRF4 PAX5 REL

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....